

Maurizio Rainisio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4526367/publications.pdf>

Version: 2024-02-01

22
papers

4,391
citations

430874

18
h-index

752698

20
g-index

24
all docs

24
docs citations

24
times ranked

3027
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study. <i>Lancet, The</i> , 2001, 358, 1119-1123.	13.7	1,421
2	Long-term intravenous epoprostenol infusion in primary pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , 2002, 40, 780-788.	2.8	1,290
3	Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1380-1386.	2.8	334
4	Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2009.	7.4	330
5	Clinical trial design and new therapies for pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801908.	6.7	142
6	Tezosentan in patients with acuteheart failure and acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003, 41, 1452-1457.	2.8	134
7	Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. <i>Journal of the American College of Cardiology</i> , 2003, 42, 140-147.	2.8	113
8	New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension. <i>Journal of the American College of Cardiology</i> , 2013, 62, D82-D91.	2.8	113
9	Clinical and Hemodynamic Effects of Bosentan Dose Optimization in Symptomatic Heart Failure Patients with Severe Systolic Dysfunction, Associated with Secondary Pulmonary Hypertension â€” A Multi-Center Randomized Study. <i>Cardiology</i> , 2008, 109, 273-280.	1.4	89
10	Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). <i>American Heart Journal</i> , 2005, 150, 46-53.	2.7	67
11	Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study. <i>Journal of Cardiac Failure</i> , 2015, 21, 179-188.	1.7	65
12	Neurohormonal Activation in Acute Heart Failure: Results from VERITAS. <i>Cardiology</i> , 2011, 119, 96-105.	1.4	56
13	The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor) Tj ETQq1 1 0,784314 rgBT /Ov	7.1	55
14	Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension. <i>Current Therapeutic Research</i> , 2002, 63, 227-246.	1.2	32
15	Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the <sc>VERITAS</sc> study. <i>European Journal of Heart Failure</i> , 2014, 16, 1362-1371.	7.1	28
16	Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. <i>Journal of Cardiac Failure</i> , 2016, 22, 815-822.	1.7	27
17	A Case-Controlled Study with Dornase Alfa to Evaluate Impact on Disease Progression over a 4-Year Period. <i>Respiration</i> , 2001, 68, 160-164.	2.6	22
18	Systolic blood pressure reduction during the first 24â€”h in acute heart failure admission: friend or foe?. <i>European Journal of Heart Failure</i> , 2018, 20, 317-322.	7.1	20

#	ARTICLE	IF	CITATIONS
19	Echocardiographic ejection fraction in patients with acute heart failure: correlations with hemodynamic, clinical, and neurohormonal measures and short-term outcome. <i>European Journal of Heart Failure</i> , 2005, 7, 815-819.	7.1	19
20	Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. <i>PLoS ONE</i> , 2017, 12, e0181557.	2.5	15
21	NRD.E1, an innovative non- μ opioid therapy for painful diabetic peripheral neuropathy- A randomized proof of concept study. <i>European Journal of Pain</i> , 0, , .	2.8	2
22	A SARS-CoV-2 Infection High-Uptake Program on Healthcare Workers and Cancer Patients of the National Cancer Institute of Naples, Italy. <i>Healthcare (Switzerland)</i> , 2022, 10, 205.	2.0	0